Incyte Corp Stock Price, News & Analysis

Incyte (NASDAQ:INCY) and Enable Injections announced a strategic partnership on October 27, 2025 to develop and commercialize Incyte’s investigational mutCALR monoclonal antibody (INCA033989) using Enable’s enFuse® On-Body Delivery System.

Under the agreement Incyte obtains a worldwide, exclusive license to use enFuse with INCA033989 in essential thrombocythemia (ET) and myelofibrosis (MF), with potential expansion to other assets and indications. Financial terms include an upfront technology access fee, potential R&D and commercial milestones, and a transfer price for clinical and commercial supply of enFuse devices. enFuse is designed to deliver large-volume subcutaneous doses and enable flexible site-of-care, including at-home self-administration.

Incyte (NASDAQ:INCY) reported eight-week Phase 3b TRuE-AD4 results showing Opzelura (ruxolitinib cream) 1.5% significantly improved moderate atopic dermatitis in adults with inadequate response, intolerance or contraindication to topical corticosteroids and calcineurin inhibitors. At Week 8, 70.0% achieved EASI75 versus 18.5% vehicle and 61.3% achieved IGA-TS versus 13.6% vehicle (P<0.0001 each). Itch improved as early as Day 2 and 62.5% reached Itch NRS4 by Week 8. No serious infections, MACE, malignancies or thromboses were reported during the 8-week vehicle-controlled period. Incyte expects to file a Type-II variation for EU approval by year-end.

Lilly (NYSE: LLY) reported 52-week Phase 3 BRAVE-AA-PEDS results showing once-daily oral baricitinib 4 mg produced substantial hair regrowth in adolescents (ages 12 to <18) with severe alopecia areata.

Key one-year outcomes: 54.1% achieved ≥80% scalp hair coverage (SALT ≤20) on 4 mg versus 31% on 2 mg; 41.2% on 4 mg achieved ≥90% scalp coverage (SALT ≤10). In the severe-disease subgroup (SALT 50–94), 71% on 4 mg achieved successful regrowth. Eyebrow and eyelash regrowth rates were also higher on 4 mg. Safety was consistent with prior trials; no deaths, opportunistic infections, MACEs, or VTEs were reported.

Lilly plans to submit these adolescent data to global regulators for a potential label update for Olumiant and to enroll younger children in BRAVE-AA-PEDS.

Incyte (Nasdaq:INCY) presented Phase 1 data at ESMO 2025 for two programs: INCA33890 (TGFβR2×PD-1) in microsatellite stable (MSS) colorectal cancer and INCB161734 (KRAS G12D) in pancreatic ductal adenocarcinoma (PDAC).

Key points: INCA33890 (RDE cohort n=239) showed a 15.2% ORR in metastatic MSS colorectal cancer (n=105) with manageable immune-related safety; registrational program planned to start in 2026. INCB161734 (expansion doses 600 mg and 1,200 mg) showed PDAC ORRs of 20% and 34% with high DCRs (64% and 86%), no DLTs, and MTD not reached; durability data expected in H1 2026.

Incyte (Nasdaq:INCY) announced that Phase 1 proof-of-concept data for two investigational therapies—INCA33890 (TGFβR2×PD-1 bispecific) and INCB161734 (oral KRAS G12D inhibitor)—will be presented as oral presentations at the ESMO Congress 2025 in Berlin.

INCA33890 is scheduled for a mini oral session on October 17, 2025, 8:00–9:30 a.m. ET (Abstract #1522). INCB161734 is scheduled for a proffered paper session on October 19, 2025, 8:45–10:20 a.m. ET (Abstract #916O). An in-person analyst and investor event discussing these data will be held on October 19, 2025, 1:30–3:00 p.m. ET, with a webcast available via Incyte’s Events and Presentations page and replay for 30 days.

Incyte (NASDAQ: INCY) said it will report third quarter 2025 financial results with a press release on October 28, 2025 at 7:00 a.m. ET and a conference call and webcast on October 28, 2025 at 8:00 a.m. ET. Domestic dial-in is 877-407-3042, international dial-in is 201-389-0864, and the conference ID is 13756261. A replay of the call will be available for 30 days (U.S. replay 877-660-6853; international replay 201-612-7415) and the webcast replay with slides will be available at Investor.Incyte.com for 90 days.

Incyte (Nasdaq:INCY) has granted equity inducement awards to David H. Gardner, the company's new Executive Vice President and Chief Strategy Officer. The compensation package includes:

• 42,899 stock options at $84.73 per share with a ten-year term
• 9,429 restricted stock units (RSUs)
• 23,573 target performance shares tied to TSR performance

The awards, approved under Nasdaq Rule 5635(c)(4), include specific vesting schedules and performance criteria over a three-year period beginning January 1, 2025.

Incyte (Nasdaq:INCY) has appointed Dave Gardner as Executive Vice President and Chief Strategy Officer, effective September 22, 2025. Gardner brings over 20 years of experience in pharmaceutical and biotechnology investing and advising, most recently serving as Partner at Rock Springs Capital Management.

In his new role, Gardner will be responsible for the company's strategy and business development, joining the Executive Leadership Team. He previously held positions at BlackRock as Vice President and Equity Research Analyst. The appointment coincides with the retirement of Vijay Iyengar, M.D., who served nine years as EVP and Head of Global Medical Affairs and Product and Partnership Strategy.

Incyte (NASDAQ:INCY) has received FDA approval for Opzelura® (ruxolitinib) cream 1.5% to treat mild to moderate atopic dermatitis in non-immunocompromised children aged 2-11 years. This marks Opzelura's third FDA approval, making it the first topical JAK inhibitor approved for pediatric atopic dermatitis in the U.S.

The approval is based on the Phase 3 TRuE-AD3 trial, which demonstrated significant efficacy in achieving Investigator's Global Assessment-treatment success and 75% improvement in the Eczema Area and Severity Index. The treatment showed a consistent safety profile with no new concerns identified. This expansion addresses an estimated 2-3 million patients aged 2-11 in the U.S. affected by atopic dermatitis.